Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

BACKGROUND: To explore long-term effects of agalsidase alfa on Fabry disease cardiomyopathy in adults. METHODS: Retrospective analysis of prospectively collected data at a single center in Mainz, Germany, revealed that 45 adult patients (21 men, 24 women) had received agalsidase alfa for approximate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kampmann, Christoph, Perrin, Amandine, Beck, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587871/
https://www.ncbi.nlm.nih.gov/pubmed/26416388
http://dx.doi.org/10.1186/s13023-015-0338-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587871/
https://www.ncbi.nlm.nih.gov/pubmed/26416388
http://dx.doi.org/10.1186/s13023-015-0338-2

Ejemplares similares